Treatment with PRP-PC, an investigational platelet-based cellular therapy, may slow the decline in lung function typically experienced by people with chronic obstructive pulmonary disease (COPD), a new study with real-world data indicates. With this therapy, being developed by H-CYTE, a person’s own blood is treated in the lab…
Patients with chronic obstructive pulmonary disease (COPD) who engage in activities that put them at risk of being exposed to mold are more likely to experience disease flare-ups, a small U.K. study has found. This may be related to Aspergillus, a type of fungus that grows in damp or…
NuvoAir announced it has raised $12 million in Series A funding, which it will use to expand a digital care platform for people in the U.S. and Europe with serious respiratory disorders like chronic obstructive pulmonary disease (COPD), and to advance work on new products. The company’s NuvoAir Home…
Preventing a specific type of cell death, called necroptosis, may provide a new way of treating chronic obstructive pulmonary disease (COPD), according to data from a recent study. Patients with COPD have elevated levels of necroptosis, the study revealed. Stopping that type of cell death leads to significant reductions…
Teva Pharmaceuticals has launched the first generic version of Perforomist (formoterol fumarate inhalation solution) for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S. “Teva is pleased to provide patients with first-to-market access to a generic version of Perforomist,” Christine Baeder, senior vice president and…
Hospitalizations for chronic obstructive pulmonary disease (COPD) dropped by half after the implementation of public health measures to curb the spread of COVID-19 infections, according to a U.S. study. This reduction in COPD hospital admissions was 36% greater than “the declines seen in other serious medical conditions, including…
Glenmark Pharmaceuticals has launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva is the bioequivalent generic version of Boehringer Ingelheim’s…
Although lung cancer development is unpredictable, patients with chronic obstructive pulmonary disease (COPD) appear more likely to have the cancer and a worse prognosis compared with the general population, a Japanese study has found. Annual computed tomography (CT) screens may help with the early detection and treatment of this…
TrialSpark, a technology company that helps streamline the clinical trial process, has partnered with global biopharmaceutical company Sanofi to conduct clinical studies and accelerate the development of new treatments for chronic obstructive pulmonary disease (COPD). TrialSpark’s system is expected to improve the enrollment of Black and Hispanic COPD…
Medical Mutual of Ohio now covers Spiration Valve System (SVS), Olympus‘ minimally invasive therapy for eligible patients with severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). “This decision by Medical Mutual will provide expanded access to this critical therapy that significantly reduces lung hyperinflation associated with…
Get regular updates to your inbox.